Clinical trials: Mask
Dry Eye, Dry Eye Syndromes
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects…
- Trial name
- NCT04674358
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Wet Age-related Macular Degeneration
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
- Trial name
- DAVIO2 (NCT05381948)
- Testing
- EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
- Where
- 67 sites in United States
- Volunteers
- 161 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Allergic Rhinitis, Allergic Conjunctivitis
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube…
- Trial name
- NCT01439815
- Testing
- Fluticasone Propionate Nasal Spray, Saline Nasal Spray
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- ORA, Inc.
Keratolysis
Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
This is a phase I/II prospective, randomized, multi-center, double-masked, vehicle-controlled clinical trial evaluating the safety and efficacy of corneal collagen cross-linking the keratoprosthesis carrier tissue in subjects who…
- Trial name
- NCT02863809
- Testing
- Riboflavin, Dextran, UVA Light Source
- Where
- 13 sites in United States
- Volunteers
- 76 people
- Sponsor
- Joseph B. Ciolino, MD
Administration Site Reaction
Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment
The investigators plan to test the hypothesis that pretreatment with fentanyl prior to induction of anesthesia would result in reduce the incidence of movements and airway responses to desflurane in patients breathing…
- Trial name
- NCT01277861
- Testing
- Fentanyl
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Texas Southwestern Medical Center
Postoperative Pain, Acute
Percutaneous Auricular Neuromodulation for Postoperative Analgesia
The moderate-to-severe pain many patients experience following surgery is often treated with opioids, which are associated with side effects such as nausea/vomiting, sedation, and respiratory depression (and a risk of abuse…
- Trial name
- NCT05521516
- Testing
- Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- University of California, San Diego
Blepharitis
Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
- Trial name
- Saturn-1 (NCT04475432)
- Testing
- TP-03, 0.25%, TP-03 Vehicle
- Where
- 15 sites in United States
- Volunteers
- 421 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
- Trial name
- NCT02200770
- Testing
- Inebilizumab
- Where
- 98 sites in United States, Australia and 23 more
- Volunteers
- 231 people
- Sponsor
- MedImmune LLC
Vitreomacular Adhesion
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion.
- Trial name
- NCT00798317
- Testing
- Ocriplasmin 125µg
- Where
- 48 sites in United States, Belgium and 5 more
- Volunteers
- 326 people
- Sponsor
- ThromboGenics
Mydriasis, Dilation
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
The objectives of this study are: To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis To evaluate the safety of Nyxol To evaluate the effect of…
- Trial name
- NCT04024891
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1%
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Dry Eye Disease
Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease
- Trial name
- NCT04201574
- Testing
- ALY688 0.1%, ALY688 0.4%, Vehicle
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Allysta Pharmaceutical
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion
- Trial name
- GALILEO (NCT01012973)
- Testing
- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 73 sites in Australia, Austria and 8 more
- Volunteers
- 177 people
- Sponsor
- Bayer
Airway Morbidity
Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy
Esophagogastroduodenoscopy (EGD) is a relatively common procedure in pediatric patients undergoing evaluation for various gastrointestinal ailments.
- Trial name
- NCT01936662
- Testing
- LMA, ETT
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Indiana University
Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal…
- Trial name
- EVEREST II (NCT01846273)
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 41 sites in Hong Kong, Japan and 5 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Age-Related Macular Degeneration
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal…
- Trial name
- NCT01089517
- Testing
- E10030 plus Lucentis, Lucentis
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Ophthotech Corporation
Choroidal Neovascularization
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This multiple-center, multiple-dose and regimen, randomized, double-masked active comparator-controlled, double-masked, five parallel group, 36-week study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of…
- Trial name
- AVENUE (NCT02484690)
- Testing
- Faricimab, Ranibizumab
- Where
- 52 sites in United States
- Volunteers
- 273 people
- Sponsor
- Hoffmann-La Roche